| |
Patients remained in the cohort (n=17) |
Patients lost to follow up (n=11) |
p-value |
| Demographic characteristics |
|
|
|
| Race |
|
|
|
| African American |
10 (59%) |
5 (46%) |
0.80 |
| Hispanic |
4 (23%) |
3 (27%) |
|
| Caucasian |
2 (12%) |
3 (27%) |
|
| Asian |
1 (6%) |
0 (0%) |
|
| Gender |
|
|
|
| Male |
12 (71%) |
6 (55%) |
0.44 |
| Female |
5 (29%) |
5 (45%) |
|
| Drug Screen/Drug Use |
|
|
|
| Positive |
7 (41%) |
4 (40%) |
1.00 |
| Age (yr) |
|
|
|
| Baseline laboratory tests |
|
|
|
| CD4 (cells/uL) |
147.2 (134.9) |
145 (147.5) |
0.97 |
| CD4 percent |
10.29 (8.46) |
10.55 (8.35) |
0.94 |
| Log VL (copies/ml) |
5.00 (0.70) |
5.28 (0.70) |
0.30 |
| Total Cholesterol (mg/dL) |
179.7 (51.04) |
173.3 (57.31) |
0.76 |
| Triglycerides (mg/dL) |
138.3 (77.11) |
133.9 (55.3) |
0.87 |
| HDL (mg/dL) |
46.56 (11.85) |
38.73 (13.36) |
0.12 |
| LDL (mg/dL) |
105.6 (53.08) |
107.8 (52.12) |
0.91 |
| IL-6 |
7.27 (9.45) |
21.55 (30.04) |
0.15 |
| Homocysteine (units) |
9.94 (2.89) |
10.17 (3.42) |
0.84 |
Changes in laboratory values between baseline and week 48